Rangitikei, New Zealand

Maithri Siriwardena

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Otago Innovation Limited. Active years: 2017.

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Maithri Siriwardena: Innovator in Cardiovascular Therapeutics

Introduction

Maithri Siriwardena is a notable inventor based in Rangitikei, New Zealand. She has made significant contributions to the field of cardiovascular therapeutics. Her innovative work focuses on developing compounds and compositions that utilize a B-type natriuretic signal peptide fragment agent for the treatment and prevention of cardiovascular diseases, disorders, and conditions.

Latest Patents

Maithri holds 1 patent for her groundbreaking invention in cardiovascular therapeutics. This patent encompasses methods and compositions that aim to improve the treatment options available for patients suffering from various cardiovascular issues.

Career Highlights

Throughout her career, Maithri has worked with several organizations that emphasize innovation in medical technologies. Notably, she has been associated with Otago Innovation Limited and Upstream Medical Technologies Limited. These experiences have allowed her to refine her skills and contribute to advancements in healthcare.

Collaborations

Maithri has collaborated with esteemed professionals in her field, including Christopher Joseph Pemberton and Arthur Mark Richards. These partnerships have further enhanced her research and development efforts in cardiovascular therapeutics.

Conclusion

Maithri Siriwardena's contributions to cardiovascular therapeutics highlight her dedication to improving healthcare outcomes. Her innovative spirit and collaborative efforts continue to inspire advancements in medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…